Importance of resectability status in neoadjuvant treatment for pancreatic cancer

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 7, 2015, Pages 563-570

  Sho, Masayuki ^a   Akahori, Takahiro ^a   Tanaka, Toshihiro ^a   Kinoshita, Shoichi ^a   Nagai, Minako ^a   Tamamoto, Tetsuro ^a   Ohbayashi, Chiho ^a   Hasegawa, Masatoshi ^a   Kichikawa, Kimihiko ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adjuvant treatment; Borderline resectable; Neoadjuvant treatment; Pancreatic cancer; Surgery

Indexed keywords

FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BORDERLINE RESECTABLE PANCREATIC CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEPATIC ARTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PORTAL VEIN; RETROSPECTIVE STUDY; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC VEIN; SURVIVAL TIME; ADJUVANT THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; NEOADJUVANT THERAPY; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84932192847     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.258     Document Type: Article

References (40)

1. Ma J, Siegel R, Jemal A,. Pancreatic Cancer Death Rates by Race Among US Men and Women, 1970-2009. J Natl Cancer Inst. 2013; 105: 1694-700.
2. Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, et al., Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Pancreas. 2012; 41: 985-92.
3. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al., Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-8.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6.
5. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-25.
6. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-703.
7. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, et al., Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008; 12: 701-6.
8. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al., Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008; 247: 456-62.
9. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al., Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-77.
10. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al., A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009; 101: 908-15.
11. Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, et al., Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer. 2011; 11: 346.
12. Sutton JM, Abbott DE,. Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. World J Gastroenterol. 2014; 20: 15564-79.
13. Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M,. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol. 2014; 20: 9374-83.
14. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM,. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013; 144: 1316-26.
15. Heinemann V, Haas M, Boeck S,. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013; 24: 2484-92.
16. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al., Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013; 20: 2787-95.
17. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al., Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014; 155: 977-88.
18. Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, et al., Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013; 20: 3794-801.
19. Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, et al., Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013; 258: 1040-50.
20. Katz MH, Crane CH, Varadhachary G,. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol. 2014; 24: 105-12.
21. Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, et al., Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival. Ann Surg Oncol. 2014; 21: 1530-7.
22. Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, et al., Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2013; 20: 197-205.
23. Tempero MA, Malafa MP, Behrman SW, Benson AB, 3rd, Casper ES, Chiorean EG, et al., Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014; 12: 1083-93.
24. Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Doh J, et al., Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci. 2011; 18: 235-9; discussion 9-40.
25. Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, et al., Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP. 2013; 14: 618-25.
26. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VW, Sandroussi C,. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011; 15: 2059-69.
27. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M,. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011; 35: 1580-9.
28. Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, et al., Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011; 104: 155-61.
29. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA,. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2009; 12: 73-9.
30. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, et al., Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010; 101: 587-92.
31. Araujo RL, Gaujoux S, Huguet F, Gonen M, D'Angelica MI, DeMatteo RP, et al., Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis. HPB (Oxford). 2013; 15: 574-80.
32. Takahashi H, Ogawa H, Ohigashi H, Gotoh K, Yamada T, Ohue M, et al., Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery. 2011; 150: 547-56.
33. Cheng TY, Sheth K, White RR, Ueno T, Hung CF, Clary BM, et al., Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006; 13: 66-74.
34. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al., Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014; 32: 504-12.
35. Kato K, Yamada S, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, et al., Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: influence of resection margin status on survival. Pancreas. 2009; 38: 605-12.
36. Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, et al., Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg. 2012; 215: 41-51; discussion -2.
37. Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, et al., Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013; 20: 590-600.
38. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, et al., Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. Ann Surg Oncol. 2015; 22: 1153-9.
39. Sherman WH, Chu K, Chabot J, Allendorf J, Schrope BA, Hecht E, et al., Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 673-80.
40. Yanagimoto H, Ishii H, Nakai Y, Ozaka M, Ikari T, Koike K, et al., Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. J Hepatobiliary Pancreat Sci. 2014; 21: 761-6.